NCT03634956

Brief Summary

Thyroidectomy is a frequently performed surgeon by the head and neck and endocrine surgeons. In recent years, surgical techniques and technological developments have resulted in a significant reduction in complication rates. Despite these advances, there is still a great deal of anxiety about the sound problems that can be experienced in patients after surgery. In the past years,the investigators have tried to prevent recurrent nerve paralysis by using intraoperative nerve monitoring (IONM). The use of IONM has begun to be preferred by many surgeons in the investigator's country. However, the use of IONM decreases the number of recurrent nerve paralysis are still being discussed and many studies have been done. In this study, it is aimed to prevent the formation of recurrent nerve paralysis in order to safely carry out the IONM by removing the effects of neuromuscular blockade drugs using sugammadex sodium medicine in the thyroidectomy operations.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 13, 2018

Completed
1 day until next milestone

Study Start

First participant enrolled

August 14, 2018

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 17, 2018

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 14, 2019

Completed
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 14, 2019

Completed
Last Updated

August 20, 2018

Status Verified

August 1, 2018

Enrollment Period

6 months

First QC Date

August 13, 2018

Last Update Submit

August 16, 2018

Conditions

Keywords

multinoduler goitrethyroid cancersugammadex sodiumintraoperative nerve monitorization

Outcome Measures

Primary Outcomes (1)

  • Vocal cord paralysis

    postoperative vocal cord examination will be performed and the recurrent laryngeal nerve will be examined.

    postop 15th days

Secondary Outcomes (4)

  • vagal nerve conduction value(V1)

    15 to 45 minutes of surgery

  • vagal nerve conduction value after lob resection(V2)

    30 to 90 minutes of surgery

  • first detected vagal nerve conduction value(V0)

    5 to 25 minutes of surgery

  • TOF time

    10 to 90 minutes of surgery

Study Arms (1)

Group I.IONM in thyroid surgery

EXPERIMENTAL

Group I.IONM in thyroid surgery.Once the vagus has been detected,nerve conduction data will be detected with IONM. If the muscle relaxant effect is not detected, it will be detected with TOF device.

Drug: Group B. Sugammadex sodium-IONM

Interventions

Group B.the vagal nerve is detected and then 2 mg / kg of sugammadex sodium is administered to remove the muscle relaxant effect

Also known as: Sugammadex sodium intervention group
Group I.IONM in thyroid surgery

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinical diagnosis of Multinodular goiter,
  • Clinical diagnosis of thyroid cancer
  • Clinical diagnosis of noduler goatr,
  • Clinical diagnosis of basedow Graves disease,

You may not qualify if:

  • Patients with bleeding diathesis,
  • Patients who have previously undergone laryngeal surgery (vocal polyps, nodules or laryngeal cancer),

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Lutfiye NBGH

Istanbul, 34300, Turkey (Türkiye)

RECRUITING

Related Publications (2)

  • Empis de Vendin O, Schmartz D, Brunaud L, Fuchs-Buder T. Recurrent Laryngeal Nerve Monitoring and Rocuronium: A Selective Sugammadex Reversal Protocol. World J Surg. 2017 Sep;41(9):2298-2303. doi: 10.1007/s00268-017-4004-9.

    PMID: 28349321BACKGROUND
  • Barczynski M, Konturek A, Cichon S. Randomized clinical trial of visualization versus neuromonitoring of recurrent laryngeal nerves during thyroidectomy. Br J Surg. 2009 Mar;96(3):240-6. doi: 10.1002/bjs.6417.

    PMID: 19177420BACKGROUND

MeSH Terms

Conditions

Vocal Cord ParalysisThyroid Neoplasms

Condition Hierarchy (Ancestors)

Laryngeal DiseasesRespiratory Tract DiseasesOtorhinolaryngologic DiseasesVagus Nerve DiseasesCranial Nerve DiseasesNervous System DiseasesParalysisNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsEndocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsEndocrine System DiseasesThyroid Diseases

Study Officials

  • Turgut Donmez, surgeon

    Lütfiye Nuri Burat Goverment Hastanesi

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Turgut Donmez, surgeon

CONTACT

Mehmet Emin Gunes, surgeon

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Model Details: Group A. Sugammadex sodium-IONM in thyroid surgery Group B.Standart technique-IONM in thyroid surgery
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

August 13, 2018

First Posted

August 17, 2018

Study Start

August 14, 2018

Primary Completion

February 14, 2019

Study Completion

March 14, 2019

Last Updated

August 20, 2018

Record last verified: 2018-08

Data Sharing

IPD Sharing
Will share

Patients who are accepted to participate in the study will be gathered in the pool. The patients' data will be entered on the computer. The computer and patients will be randomized and set up on the day of surgery. The preop, perop and postop data of the patients will be recorded on the computer.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
14.08.2018-14.02.2019
Access Criteria
the study data will be stored securely on the researcher's turgut donmez personal computer. It will be available to researchers participating in the study alone

Locations